Home > Field of Cooperation > Health Research > TB-ACQUIRE: Mechanisms and Relevance of Resistance Against Novel Anti-TB Drugs
TB-ACQUIRE: Mechanisms and Relevance of Resistance Against Novel Anti-TB Drugs |
| Principal Investigator / Affiliation | Vitali Sintchenko (Professor) / The University of Sydney  Australia |
|---|---|
Stefan Oehlers (Principal Investigator) / Agency for Science, Technology and Research (A*STAR)  Singapore |
|
Catherine Ann Sacopon (Science Research Specialist II) / Research Institute For Tropical Medicine  Philippines |
|
| Year Adopted | 2024 |
| Research Period | 3 years |
| General Description of the Research Project | TB-ACQUIRE addresses a crucial knowledge gap by investigating the acquisition and spread of resistance against new life-saving TB drugs (BPaL/M). Integrating in vitro, in vivo and ‘in human’ studies with cutting-edge long-read sequencing technology and genomics, TB-ACQUIRE will uncover M. tuberculosis evolution under selective drug pressure, exploring genetic markers and compensatory mechanisms of drug resistance acquisition and spread. TB-ACQUIRE will contribute to national, regional, and global TB control efforts, and inform updates of the 2023 WHO Drug Resistance Mutation Catalogue. |
| Photo Gallery | |
| Reports | |
| Links |
Researchers
| Principal Investigator / Country of Research Team | 
Vitali Sintchenko Australia
Stefan Oehlers Republic of Singapore
Catherine Ann Sacopon the Philippines |
|---|